抗原
癌症免疫疗法
癌细胞
黑色素瘤
癌症
免疫
癌症研究
免疫疗法
免疫系统
材料科学
生物
免疫学
遗传学
作者
Lin Ma,Lu Diao,Zuofu Peng,Yun Jia,Huimin Xie,Baisong Li,Jianting Ma,Meng Zhang,Lifang Cheng,Dawei Ding,Xuenong Zhang,Huabing Chen,Fengfeng Mo,Honglv Jiang,Guoqiang Xu,Fenghua Meng,Zhiyuan Zhong,Mi Liu
标识
DOI:10.1002/adma.202104849
摘要
Tumor tissues/cells are the best sources of antigens to prepare cancer vaccines. However, due to the difficulty of solubilization and delivery of water-insoluble antigens in tumor tissues/cells, including water-insoluble antigens into cancer vaccines and delivering such vaccines efficiently to antigen-presenting cells (APCs) remain challenging. To solve these problems, herein, water-insoluble components of tumor tissues/cells are solubilized by 8 m urea and thus whole components of micrometer-sized tumor cells are reasssembled into nanosized nanovaccines. To induce maximized immunization efficacy, various antigens are loaded both inside and on the surface of nanovaccines. By encapsulating both water-insoluble and water-soluble components of tumor tissues/cells into nanovaccines, the nanovaccines are efficiently phagocytosed by APCs and showed better therapeutic efficacy than the nanovaccine loaded with only water-soluble components in melanoma and breast cancer. Anti-PD-1 antibody and metformin can improve the efficacy of nanovaccines. In addition, the nanovaccines can prevent lung cancer (100%) and melanoma (70%) efficiently in mice. T cell analysis and tumor microenvironment analysis indicate that tumor-specific T cells are induced by nanovaccines and both adaptive and innate immune responses against cancer cells are activated by nanovaccines. Overall, this study demonstrates a universal method to make tumor-cell-based nanovaccines for cancer immunotherapy and prevention.
科研通智能强力驱动
Strongly Powered by AbleSci AI